Aethlon Stock Pulls Back: What's Going On?

9/18/2026
Impact: -50
Healthcare

Aethlon Medical Inc (NASDAQ: AEMD) shares fell 9.29% to $6.15 following a significant surge of over 300% the previous day after announcing a merger with North Immunology. The all-stock deal will create a combined entity valued at approximately $346.5 million, which will focus on advancing North Immunology's lead drug candidate, NOR-101. Existing Aethlon shareholders will retain about 4.75% of the new company, with the deal pending shareholder and regulatory approval expected to close in early 2027.

AI summary, not financial advice

Share: